Abstract
Challenges in clinical data sharing and the need to protect data privacy have led to the development and popularization of methods that do not require directly transferring patient data. In neuroimaging, integration of data across multiple institutions also introduces unwanted biases driven by scanner differences. These scanner effects have been shown by several research groups to severely affect downstream analyses. To facilitate the need of removing scanner effects in a distributed data setting, we introduce distributed ComBat, an adaptation of a popular harmonization method for multivariate data that borrows information across features. We present our fast and simple distributed algorithm and show that it yields equivalent results using data from the Alzheimer's Disease Neuroimaging Initiative. Our method enables harmonization while ensuring maximal privacy protection, thus facilitating a broad range of downstream analyses in functional and structural imaging studies.
Original language | English |
---|---|
Article number | 118822 |
Journal | NeuroImage |
Volume | 248 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- ComBat
- Distributed analysis
- Harmonization
- Privacy-preserving
- Site effect
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Privacy-preserving harmonization via distributed ComBat'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Privacy-preserving harmonization via distributed ComBat. / the Alzheimer's Disease Neuroimaging Initiative.
In: NeuroImage, Vol. 248, 118822, 03.2022.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Privacy-preserving harmonization via distributed ComBat
AU - the Alzheimer's Disease Neuroimaging Initiative
AU - Chen, Andrew A.
AU - Luo, Chongliang
AU - Chen, Yong
AU - Shinohara, Russell T.
AU - Shou, Haochang
N1 - Funding Information: This work was supported by the National Institute of Neurological Disorders and Stroke (grant numbers R01 NS085211 and R01 NS060910), the National Multiple Sclerosis Society (RG-1707-28586), the National Institute of Mental Health (R01 MH123550), and a seed grant from the University of Pennsylvania Center for Biomedical Image Computing and Analytics (CBICA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Funding Information: The majority of the data used in this paper are derived from the ADNI study. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: Yong Chen’s research was supported in part by Patient-Centered Outcomes Research Institute (PCORI) Project Program Award (ME-2019C3-18315). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Funding Information: This work was supported by the National Institute of Neurological Disorders and Stroke (grant numbers R01 NS085211 and R01 NS060910), the National Multiple Sclerosis Society (RG-1707-28586), the National Institute of Mental Health (R01 MH123550), and a seed grant from the University of Pennsylvania Center for Biomedical Image Computing and Analytics (CBICA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Yong Chen's research was supported in part by Patient-Centered Outcomes Research Institute (PCORI) Project Program Award (ME-2019C3-18315). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. The majority of the data used in this paper are derived from the ADNI study. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Publisher Copyright: © 2021
PY - 2022/3
Y1 - 2022/3
N2 - Challenges in clinical data sharing and the need to protect data privacy have led to the development and popularization of methods that do not require directly transferring patient data. In neuroimaging, integration of data across multiple institutions also introduces unwanted biases driven by scanner differences. These scanner effects have been shown by several research groups to severely affect downstream analyses. To facilitate the need of removing scanner effects in a distributed data setting, we introduce distributed ComBat, an adaptation of a popular harmonization method for multivariate data that borrows information across features. We present our fast and simple distributed algorithm and show that it yields equivalent results using data from the Alzheimer's Disease Neuroimaging Initiative. Our method enables harmonization while ensuring maximal privacy protection, thus facilitating a broad range of downstream analyses in functional and structural imaging studies.
AB - Challenges in clinical data sharing and the need to protect data privacy have led to the development and popularization of methods that do not require directly transferring patient data. In neuroimaging, integration of data across multiple institutions also introduces unwanted biases driven by scanner differences. These scanner effects have been shown by several research groups to severely affect downstream analyses. To facilitate the need of removing scanner effects in a distributed data setting, we introduce distributed ComBat, an adaptation of a popular harmonization method for multivariate data that borrows information across features. We present our fast and simple distributed algorithm and show that it yields equivalent results using data from the Alzheimer's Disease Neuroimaging Initiative. Our method enables harmonization while ensuring maximal privacy protection, thus facilitating a broad range of downstream analyses in functional and structural imaging studies.
KW - ComBat
KW - Distributed analysis
KW - Harmonization
KW - Privacy-preserving
KW - Site effect
UR - http://www.scopus.com/inward/record.url?scp=85123878459&partnerID=8YFLogxK
U2 - 10.1016/j.neuroimage.2021.118822
DO - 10.1016/j.neuroimage.2021.118822
M3 - Article
C2 - 34958950
AN - SCOPUS:85123878459
SN - 1053-8119
VL - 248
JO - NeuroImage
JF - NeuroImage
M1 - 118822
ER -